Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Champions Oncology (CSBR)
:CSBR
Holding CSBR?
Track your performance easily
Earnings Data
Report Date
Mar 18, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.16Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Sep 13, 2018
|% Change Since: 70.38%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, positive financial results, improved margins, and a solid cash position. However, there are concerns about potential revenue and cost volatility and a challenging funding environment. Overall, the sentiment is positive with strong confidence in future growth.Company Guidance
During the Champions Oncology Q2 2025 earnings call, CEO Ronnie Morris highlighted the company's strong financial performance and strategic initiatives. The company reported a 17% year-over-year revenue increase to $13.5 million, with a GAAP income from operations of $700,000 compared to a loss of $1.9 million in the prior year. Adjusted EBITDA stood at $1.1 million, reflecting improved operational efficiencies. Champions Oncology anticipates introducing a new revenue stream through data licensing, expected to significantly impact revenue, margins, and enterprise value. The company also noted a sustained growth in their core services business, driven by the PDX bank and multiomic data, with gross margins improving to 45% from 43% last year. Looking ahead, they project fiscal 2025 revenue growth between 10% and 15% and a positive quarterly adjusted EBITDA, despite anticipated short-term fluctuations in research service revenues.Revenue Growth
Revenue of $13.5 million, a 17% increase over the same period last year.
Positive Financial Results
Income from operations was $700,000, compared to a loss of $1.9 million in the prior year. Adjusted EBITDA was $1.1 million, compared to an adjusted loss of $1.4 million in the year-ago period.
Improved Gross Margin
Gross margin improved to 45% compared to 43% for the same period last year.
Cost Reductions
R&D expenses decreased to $1.7 million from $2.5 million in the year-ago period. G&A expenses decreased to $1.6 million from $2.1 million.
Strong Cash Position
Ended the quarter with $2.8 million of cash on the balance sheet and no debt.
New Revenue Stream
Introduction of a new revenue stream through data licensing expected to positively impact revenue, margins, and enterprise value.
---
CSBR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CSBR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Dec 11, 2024 | $5.84 | $5.16 | -11.64% |
| Sep 11, 2024 | $4.07 | $4.46 | +9.58% |
| Jul 18, 2024 | $4.92 | $5.04 | +2.44% |
| Mar 12, 2024 | $5.67 | $5.50 | -3.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Champions Oncology (CSBR) report earnings?
Champions Oncology (CSBR) is schdueled to report earning on Mar 18, 2025, TBA Not Confirmed.
What is Champions Oncology (CSBR) earnings time?
Champions Oncology (CSBR) earnings time is at Mar 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSBR EPS forecast?
CSBR EPS forecast for the fiscal quarter 2025 (Q3) is -0.01.
---